Solio brings combo therapy device for pain relief to market
Solio (Tel Aviv, Israel) has released its Alfa Plus device, which provides relief from chronic pain in addition to pain from trauma, sports injury, and menstruation, commercially. The device, which can be used at home, combines radio frequency (RF), infrared (IR) technologies, and low-level laser therapy (LLLT).
Placed directly on the site of pain, four RF diodes noninvasively penetrate the skin with deep heating. This increases blood circulation and accelerates tissue regeneration, while reducing inflammation, muscle aches, stiffness, and pain. In addition, it uses dual optical energy in the IR and red spectrum for treating skin pain and stiffness; bipolar RF energy for deep penetration technology that reaches muscles and joints, increasing blood circulation, treating pain, and muscle spasms; and LLLT to treat skin tissues.
"The effect is comparable to trigger-point therapy, but with the advantage of deep heat, as Alfa Plus stimulates the body's natural healing mechanisms," explains Shahak "Chuck" Cohen, founder of Solio. "By increasing the blood circulation, both oxygen and nutrients are drawn to the affected area. Essentially, Alfa Plus gently but effectively coaxes the body into healing itself."
A soon-to-be-published clinical study from Israel studied Alfa Plus together with trigger-point treatment in over 100 patients, with 90 reporting significant reduction in their lower-back pain. And most patients prefer nonpharmaceutical approaches to pain relief, as reported by cosmetic and medical dermatologist, Dr. Judith Hellman, professor at Mount Sinai Medical Center (New York, NY).
How long the Alfa Plus needs to be used varies from user to user. For menstrual pain, Alfa Plus advises 15- to 20-minute treatment sessions. For chronic pain, the device should be used twice a day for the first few days before scaling back to once a day for two to three months, and finally, no more than four times a week to avoid overstimulation.
The company plans to continue expanding its therapeutic line into the American market.
For more information, please visit soliotherapy.com.